Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Prolonged Monthly Myelosuppressive Maintenance Chemotherapy in Acute Myeloid Leukemia: The AMLCG Experience.

Utz O. Krug, MD, Wolfgang E. Berdel, MD, Maria Cristina Sauerland, Achim Heinecke, PhD, Bernhard Josef Wormann, MD, Wolfgang Hiddemann, MD, Thomas Buchner, MD

Blood (2007) 110 (11): 1856.

https://doi.org/10.1182/blood.V110.11.1856.1856

Published: 2007

Journal Articles

The Outcome in AML Is Predicted by Cytogenetics, NPM1/FLT3 Mutation, Age and Sex, but Not by Treatment Variables.

Thomas Buchner, Wolfgang E. Berdel, Utz O. Krug, Torsten Haferlach, Claudia Haferlach, Susanne Schnittger, Wolfgang Kern, Carsten Müller-Tidow, Karsten Spiekermann, Jan Braess, Sarah Volpert, Maria Cristina Sauerland, Achim Heinecke, Bernhard Josef Wormann, Wolfgang Hiddemann

Blood (2007) 110 (11): 593.

https://doi.org/10.1182/blood.V110.11.593.593

Published: 2007

Journal Articles

Changes in the Hierarchy of Risk Factors with Older Age in De-Novo Acute Myeloid Leukemia (AML).

Thomas Buchner, MD, Wolfgang E. Berdel, MD, Claudia Schoch, MD, Torsten Haferlach, MD, Hubert L. Serve, MD, Joachim Kienast, MD, Susanne Schnittger, PhD, Wolfgang Kern, MD, Joelle Tchinda, MD, Albrecht Reichle, MD, Peter Staib, MD, Wolf-Dieter Ludwig, MD, Carlo Aul, MD, Maria Cristina Sauerland, Dipl Math, Achim Heinecke, PhD, Bernhard Josef Wormann, MD, Wolfgang Hiddemann, MD

Blood (2006) 108 (11): 1977.

https://doi.org/10.1182/blood.V108.11.1977.1977

Published: 2006

Journal Articles

Intensification of Induction by High-Dose AraC and Outcome in Older Patients with De-Novo Acute Myeloid Leukemia (AML) and Subsets.

Thomas Buchner, MD, Wolfgang E. Berdel, MD, Claudia Schoch, MD, Torsten Haferlach, MD, Joelle Tchinda, MD, Susanne Schnittger, PhD, Wolfgang Kern, MD, Albrecht Reichle, MD, Peter Staib, MD, Hubert L. Serve, MD, Wolf-Dieter Ludwig, MD, Maria Cristina Sauerland, Dipl Math, Achim Heinecke, PhD, Bernhard Josef Wormann, MD, Wolfgang Hiddemann, MD

Blood (2006) 108 (11): 1978.

https://doi.org/10.1182/blood.V108.11.1978.1978

Published: 2006

Journal Articles

NPM-1, but Not FLT3-ITD Mutations Predict Early Blast Cell Clearance and CR Rate in Patients with Normal Karyotype AML or High-Risk Myelodysplastic Syndrome (MDS).

Karsten Spiekermann, MD, Annika Dufour, PhD, Gudrun Mellert, Evelin Zellmeier, Jan Braess, MD, Stefan K. Bohlander, MD, Michaela Feuring-Buske, MD, Christian Buske, MD, Susanne Fritsch, MD, Achim Heinecke, PhD, Maria C. Sauerland, PhD, Eva Hoster, PhD, Michael Unterhalt, MD, Wolfgang E. Berdel, MD, Bernhard Josef Wormann, MD, Thomas Buchner, MD, Wolfgang Hiddemann, MD, Acute Myeloid Leukemia Cooperative Group (AMLCG)

Blood (2006) 108 (11): 805.

https://doi.org/10.1182/blood.V108.11.805.805

Published: 2006

Journal Articles

Prospective Multicenter Study for Patients with Therapy - Related Acute Myeloid Leukemia (AML) Using Intensive Induction and Postremission Therapy.

Bernhard Josef Wormann, MD, Claudia Schoch, MD, Albrecht Reichle, MD, Peter Staib, MD, Wolf-Dieter Ludwig, MD, Maria Cristina Sauerland, Achim Heinecke, PhD, Wolfgang E. Berdel, MD, Wolfgang Hiddemann, MD, Thomas Buchner, MD

Blood (2006) 108 (11): 2001.

https://doi.org/10.1182/blood.V108.11.2001.2001

Published: 2006

NARROW

Prolonged Monthly Myelosuppressive Maintenance Chemotherapy in Acute Myeloid Leukemia: The AMLCG Experience.

The Outcome in AML Is Predicted by Cytogenetics, NPM1/FLT3 Mutation, Age and Sex, but Not by Treatment Variables.

Changes in the Hierarchy of Risk Factors with Older Age in De-Novo Acute Myeloid Leukemia (AML).

Intensification of Induction by High-Dose AraC and Outcome in Older Patients with De-Novo Acute Myeloid Leukemia (AML) and Subsets.

NPM-1, but Not FLT3-ITD Mutations Predict Early Blast Cell Clearance and CR Rate in Patients with Normal Karyotype AML or High-Risk Myelodysplastic Syndrome (MDS).

Prospective Multicenter Study for Patients with Therapy - Related Acute Myeloid Leukemia (AML) Using Intensive Induction and Postremission Therapy.

Email alerts

ASH Publications

American Society of Hematology

Prolonged Monthly Myelosuppressive Maintenance Chemotherapy in Acute Myeloid Leukemia: The AMLCG Experience.

The Outcome in AML Is Predicted by Cytogenetics, NPM1/FLT3 Mutation, Age and Sex, but Not by Treatment Variables.

Changes in the Hierarchy of Risk Factors with Older Age in De-Novo Acute Myeloid Leukemia (AML).

Intensification of Induction by High-Dose AraC and Outcome in Older Patients with De-Novo Acute Myeloid Leukemia (AML) and Subsets.

NPM-1, but Not FLT3-ITD Mutations Predict Early Blast Cell Clearance and CR Rate in Patients with Normal Karyotype AML or High-Risk Myelodysplastic Syndrome (MDS).

Prospective Multicenter Study for Patients with Therapy - Related Acute Myeloid Leukemia (AML) Using Intensive Induction and Postremission Therapy.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only